Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy

References

• AIOM. Tumori cutanei non melanoma. Carcinoma squamocellulare cutaneo. Edizione; 2019. Available from: https://www.aiom.it/wp-content/uploads/2019/10/2019_LG_AIOM_CSquamocellulare.pdf. Accessed January 26, 2021
   Google Scholar
• AIRTUM. Analisi epidemiologica e caratterizzazione morfologica di pazienti affetti da tumore della cute non melanoma da registro nazionale AIRTUM. Available from: https://www.registri-tumori.it/cms/pubblicazioni/report-i-tumori-cutanei. Accessed January 26, 2021
   Google Scholar
• Schmults CD. High-Risk Cutaneous Squamous Cell Carcinoma: A Practical Guide for Patient Management. Berlin, Germany: Springer-Verlag Berlin Heidelberg; 2016.
   Google Scholar
• Lucas R, McMichael T, Smith W, Armstrong B. Solar Ultraviolet Radiation: Global Burden of Disease from Solar Ultraviolet Radiation. Environmental Burden of Disease Series, No. 13. Public Health and the Environment. Geneva: World Health Organization; 2006.
   Google Scholar
• Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. epidemiology, diagnostics and prevention. Eur J Cancer. 2020.
   Web of Science ®Google Scholar
• Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. treatment. Eur J Cancer. 2020.
   Google Scholar
• AIOM AIRTUM. I numeri del cancro in Italia; 2018. Available from: https://www.aiom.it/wp-content/uploads/2018/10/2018_NumeriCancro-operatori.pdf. Accessed January 26, 2021
   Google Scholar
• Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975–983. doi:10.1056/NEJM200103293441306
   PubMed Web of Science ®Google Scholar
• Riihila PM, Nissinen LM, Ala-aho R, et al. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol. 2014;134(2):498–506. doi:10.1038/jid.2013.346
   Web of Science ®Google Scholar
• Ascierto PA, Schadendorf D. Immunotherapy in non-melanoma skin cancer: updates and new perspectives. Drugs Context. 2019;8:212583. doi:10.7573/dic.212583
   Google Scholar
• Ronconi G, Piccinni C, Dondi L, et al. Identification of cases and estimate of direct costs of unresectable and advanced cutaneous squamous cell carcinoma: real-world data from a large Italian database. Br J Dermatol. 2020;10.
   Google Scholar
• Hillen U, Leiter U, Haase S, et al. Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns-results of a non-interventional study of the DeCOG. Eur J Cancer (Oxford, England: 1990). 2018;96:34–43. doi:10.1016/j.ejca.2018.01.075
   PubMed Web of Science ®Google Scholar
• Cowey CL, editor. Treatment Patterns and Outcomes Among Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) in a US Community Oncology Setting. ASCO Annual meeting; 2019.
   Google Scholar
• Sun L, Chin R-I, Gastman B, et al. Association of disease recurrence with survival outcomes in patients with cutaneous squamous cell carcinoma of the head and neck treated with multimodality therapy. JAMA Dermatol. 2019;155(4):442–447. doi:10.1001/jamadermatol.2018.5453
   PubMed Web of Science ®Google Scholar
• Berens AM, Akkina SR, Patel SA. Complications in facial Mohs defect reconstruction. Curr Opin Otolaryngol Head Neck Surg. 2017;25(4):258–264. doi:10.1097/MOO.0000000000000375
   Web of Science ®Google Scholar
• Arunachalam D, Thirumoorthy A, Devi S, Devi S. Quality of life in cancer patients with disfigurement due to cancer and its treatments. Indian J Palliat Care. 2011;17(3):184–190. doi:10.4103/0973-1075.92334
   Google Scholar
• Marcellusi A, Bini C, Peris K, et al. Cost of illness of cutaneous squamous cell carcinoma in Italy. Value Health. 2019;22(suppl3):S452. doi:10.1016/j.jval.2019.09.281
   Google Scholar
• Jarkowski A, Hare R, Loud P, et al. Systemic therapy in advanced Cutaneous Squamous Cell Carcinoma (CSCC): the roswell park experience and a review of the literature. Am J Clin Oncol. 2016;39(6):545–548. doi:10.1097/COC.0000000000000088
   PubMed Web of Science ®Google Scholar
• LIBTAYO. Summary of product characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo. Accessed January 26, 2021
   Google Scholar
• AIFA. Determina maggio 2020. Riclassificazione del medicinale per uso umano «Libtayo», ai sensi dell’articolo 8, comma 10 della legge 24 dicembre 1993, n. 537. (Determina n. DG 594/2020). (20A02750) (GU Serie Generale n.134 del 26-05-2020). 2020
   Google Scholar
• Williams C, Lewsey JD, Mackay DF, Briggs AH. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and markov decision-analytic modeling. Med Decis Making. 2017;37(4):427–39. doi:10.1177/0272989X16670617
   PubMed Web of Science ®Google Scholar
• Goeree R, Villeneuve J, Goeree J, Penrod JR, Orsini L, Tahami Monfared AA. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. J Med Econ. 2016;19(6):630–644. doi:10.3111/13696998.2016.1151432
   PubMed Web of Science ®Google Scholar
• Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU Technical Support Document 19: Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review. The National Institute for Health and Care Excellence; 2017.
   Google Scholar
• Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force–1. Value Health. 2012;15(6):796–803. doi:10.1016/j.jval.2012.06.012
   PubMed Web of Science ®Google Scholar
• Capri S, Ceci A, Terranova L, Merlo F, Mantovani L; The Members of the Italian Group for Pharmacoeconomic. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inf J. 2001;35(1):189–201. doi:10.1177/009286150103500122
   Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417–428. doi:10.1016/j.jval.2011.04.002
   PubMed Web of Science ®Google Scholar
• Ishak KJ, Benedict A. Novel methods for indirect comparison of treatments: when are they needed and how do they work? Value Outcomes Spotlight. 2016;2(1):20–23.
   Google Scholar
• Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton KJ NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. Regent Court, 30 Regent Street Sheffield, S1 4DA December 2016. 2016
   Google Scholar
• Longworth L, Yang Y, Young T, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1–224. doi:10.3310/hta18090
   PubMed Web of Science ®Google Scholar
• Scalone L, Cortesi PA, Ciampichini R, et al. Italian population-based values of EQ-5D health states. Value Health. 2013;16(5):814–822. doi:10.1016/j.jval.2013.04.008
   PubMed Web of Science ®Google Scholar
• Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. Springer; 2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK500356/. Accessed January 26, 2021
   Google Scholar
• Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non-small cell lung cancer. Health Qual Life Outcomes. 2008;6:84. doi:10.1186/1477-7525-6-84
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–690. doi:10.1038/sj.bjc.6603326
   PubMed Web of Science ®Google Scholar
• Tolley K, Goad C, Yi Y, Maroudas P, Haiderali A, Thompson G. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ. 2013;14(5):749–759. doi:10.1007/s10198-012-0419-2
   PubMed Web of Science ®Google Scholar
• Ministero della Salute. Decreto 18 ottobre 2012. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. GU Serie Generale n.23 del 28-01-2013 - Suppl. Ordinario n. 8. 2012
   Google Scholar
• Conferenza delle Regioni e delle Province Autonome. Accordo Interregionale per la compensazione della mobilità sanitaria. 20/54/CR/7b/C7 del 31 marzo 2020.
   Google Scholar
• Scaccabarozzi G, Limonta F, Amodio E. Hospital, local palliative care network and public health: how do they involve terminally ill patients? Eur J Public Health. 2017;27(1):25–30. doi:10.1093/eurpub/ckw152
   PubMed Web of Science ®Google Scholar
• Veneto R. Coordinamento regionale per le cure palliative e per la lotta al dolore. Ricorso al ricovero ospedaliero nella fase terminale della vita dei pazienti oncologici: analisi per azienda ULSS; 2006. Available from: https://www.regione.veneto.it/c/document_library/get_file?uuid=c0884b2e-3d98-4fa6-9b7c-127fae163a6d&groupId=10793. Accessed January 26, 2021
   Google Scholar
• Zucco F HOSPICE IN ITALIA. Seconda rilevazione ufficiale. 2010; Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1450_allegato.pdf. Accessed January 26, 2021
   Google Scholar
• Ministero della Salute. 2006. Nuova caratterizzazione dell’assistenza territoriale domiciliare e degli interventi ospedalieri a domicilio. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_572_allegato.pdf. Accessed January 26, 2021
   Google Scholar
• Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label Phase 3 randomised trial. Lancet Oncol. 2013;14(8):697–710. doi:10.1016/S1470-2045(13)70181-5
   PubMed Web of Science ®Google Scholar
• Lazzaro C, Bordonaro R, Cognetti F, et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. Clinicoecon Outcomes Res. 2013;5:125–135. doi:10.2147/CEOR.S41850
   PubMedGoogle Scholar
• Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer. 2010;102(1):80–86. doi:10.1038/sj.bjc.6605417
   PubMed Web of Science ®Google Scholar
• Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health. 2008;11(5):791–799. doi:10.1111/j.1524-4733.2007.00302.x
   PubMed Web of Science ®Google Scholar
• Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomico. Pharmacoeconomics-Ital-Res-Articles. 2003;5(2):53–67. doi:10.1007/BF03320605
   Google Scholar
• Fattore G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia: documento per la discussione. Pharmacoeconomics-Ital-Res-Articles. 2009;11(2):83–93. doi:10.1007/BF03320660
   Google Scholar
• Pearson I, Rothwell B, Olaye A, Knight C. Economic modeling considerations for rare diseases. Value Health. 2018;21(5):515–524. doi:10.1016/j.jval.2018.02.008
   PubMed Web of Science ®Google Scholar
• Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42. doi:10.1017/S0266462307051550
   PubMed Web of Science ®Google Scholar